High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer.
Twenty-two patients with metastatic breast cancer refractory to conventional chemotherapeutic agents were treated with 1-beta-D-arabinofuranosylcytosine (Ara-C) at a dose of 2 g/m2 over 2 h every 12 h for 3 doses at 21-day intervals. Two patients achieved partial remission, 3 patients had less than partial response.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008875:Middle Aged
D003561:Cytarabine